APLS
Apellis Pharmaceuticals, Inc.Company Information
- Company Name
- Apellis Pharmaceuticals, Inc.
- CIK
- CIK0001492422
- Category
- Large accelerated filer
- Ticker: Exchange
- APLS: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- APLS
SEC filing data through
Insider Sentiment
- Last purchase
- —
- Last sale
- 2026-02-11
- Shares purchased (TTM)
- 0
- Shares sold (TTM)
- 388,002
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 47,149
- Shares outstanding
- 127,682,000
- Ownership
- 0.04%
Earnings Market Reaction
- Filing date
- 2026-05-07
- Price on filing date
- —
- 1-month reaction
- …
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 405 | 466 | 479 | 370 | 358 | 411 | 397 | 360 | 326 | 351 | 452 | 616 | ||||||
| Accounts Receivable Net Current | 440 | 366 | 346 | 214 | 235 | 265 | 279 | 304 | 268 | 206 | 169 | 111 | ||||||
| Inventory Net | 131 | 143 | 123 | 121 | 82 | 81 | 121 | 153 | 161 | 146 | 99 | 103 | ||||||
| Prepaid Expense Current | - | - | 32 | 29 | 37 | 18 | 24 | 29 | 43 | 39 | 45 | 34 | ||||||
| Prepaid Expense And Other Assets Current | 50 | 38 | - | - | - | 30 | - | - | - | - | - | - | ||||||
| Restricted Cash Current | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Other Assets Current | - | - | 10 | 20 | 13 | 12 | 12 | 12 | 12 | 22 | 31 | 27 | ||||||
| Assets Current | 1,028 | 1,015 | 991 | 756 | 728 | 789 | 834 | 860 | 811 | 766 | 797 | 893 | ||||||
Assets Noncurrent | ||||||||||||||||||
| Operating Lease Right Of Use Asset | 19 | 18 | 20 | 15 | 15 | 16 | 17 | 16 | 15 | 17 | 15 | 17 | ||||||
| Property Plant And Equipment Net | 1 | 2 | 2 | 2 | 3 | 3 | 3 | 4 | 4 | 4 | 5 | 5 | ||||||
| Inventory Noncurrent | 28 | 35 | 41 | 48 | 61 | 76 | 46 | 23 | - | - | - | - | ||||||
| Other Assets Noncurrent | 6 | 6 | 5 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Assets | 1,083 | 1,075 | 1,059 | 821 | 807 | 885 | 902 | 904 | 832 | 789 | 818 | 916 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 49 | 57 | 39 | 54 | 55 | 39 | 43 | 38 | 27 | 38 | 18 | 28 | ||||||
| Accrued Liabilities Current | 134 | 166 | 140 | 139 | 116 | 140 | 140 | 123 | 101 | 128 | 117 | 98 | ||||||
| Convertible Debt Current | 94 | 94 | 94 | - | - | 0 | - | - | - | - | - | - | ||||||
| Operating Lease Liability Current | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 6 | 6 | 6 | 6 | 6 | ||||||
| Deferred Revenue | - | - | - | - | - | - | 2 | 2 | 4 | - | - | - | ||||||
| Liabilities Current | 283 | 324 | 280 | 201 | 178 | 186 | 191 | 169 | 215 | 248 | 186 | 175 | ||||||
Liabilities Noncurrent | ||||||||||||||||||
| Long Term Line Of Credit | 362 | 362 | 361 | 361 | 360 | 359 | 359 | 364 | - | - | - | - | ||||||
| Convertible Debt Noncurrent | - | 0 | 0 | 94 | 93 | 93 | 93 | 93 | 93 | 93 | 93 | 93 | ||||||
| Operating Lease Liability Noncurrent | 13 | 12 | 14 | 8 | 9 | 10 | 11 | 11 | 10 | 11 | 11 | 12 | ||||||
| Other Liabilities Noncurrent | 9 | 8 | 3 | 2 | 2 | 8 | 10 | 3 | 3 | 2 | 1 | 0 | ||||||
| Liabilities | 668 | 705 | 658 | 665 | 643 | 657 | 665 | 640 | 565 | 594 | 586 | 570 | ||||||
Stockholders Equity | ||||||||||||||||||
| Preferred Stock Value | 0 | 0 | 0 | 0 | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital | 3,412 | 3,385 | 3,358 | 3,329 | 3,295 | 3,267 | 3,239 | 3,209 | 3,174 | 3,036 | 2,982 | 2,955 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -2 | -2 | -2 | -3 | -3 | -3 | -3 | -3 | -4 | -4 | -1 | -1 | ||||||
| Retained Earnings Accumulated Deficit | -2,994 | -3,013 | -2,954 | -3,170 | -3,128 | -3,035 | -2,999 | -2,942 | -2,904 | -2,837 | -2,749 | -2,609 | ||||||
| Stockholders Equity | 415 | 370 | 401 | 156 | 164 | 229 | 237 | 264 | 267 | 195 | 232 | 345 | ||||||
| Liabilities And Stockholders Equity | 1,083 | 1,075 | 1,059 | 821 | 807 | 885 | 902 | 904 | 832 | 789 | 818 | 916 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | ||||||
| Common Stock Shares Issued | 128 | 127 | 127 | 126 | 126 | 124 | 122 | 122 | 121 | 120 | 118 | 118 | ||||||
| Shares Outstanding | 128 | 127 | 127 | 126 | 126 | 124 | 122 | 122 | 121 | 120 | 118 | 118 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialApellis Pharmaceuticals, Inc. (APLS) — SEC Financial Statements & Analysis
Apellis Pharmaceuticals, Inc. (APLS) is a pharmaceutical preparations company, incorporated in DE. Apellis Pharmaceuticals, Inc. trades on Nasdaq as: APLS. Apellis Pharmaceuticals, Inc. (APLS)'s most recent SEC filing is a Form 10-Q for the period ended 2026-03-31, filed with the SEC on 2026-05-07. Based on that filing, On profitability, Apellis Pharmaceuticals, Inc. posts an operating margin of 14.95%, a net margin of 12.06%, a Return on Equity (ROE) of 46.02%, a Return on Assets (ROA) of 14.10%, and a Return on Invested Capital (ROIC) of 871.91%. Per share, it reports EPS of $1.04, diluted EPS of $1.01, free cash flow per share of $0.29, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of 42.46% year-over-year, net income growth of -159.58% year-over-year, and EPS growth of -158.54% year-over-year. On the balance sheet, it maintains a current ratio of 3.63x, a quick ratio of 2.99x, working capital of $744.57M, a debt-to-equity ratio of 1.61x, a debt ratio of 0.62, an interest coverage ratio of 3.79x, free cash flow of $37.46M (TTM), and net debt of $-312.98M. Figures sourced from SEC EDGAR.
- EPS TTM
- $1.04
- ROE TTM
- 46.02%
- ROA TTM
- 14.10%
- Debt To Equity
- 1.61x
- Free Cash Flow TTM
- $37.46M
- Net Revenue TTM Growth 1Y
- 42.46%
Data as of 2026-03-31 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Apellis Pharmaceuticals, Inc. in?
Apellis Pharmaceuticals, Inc. (APLS) operates in the Pharmaceutical Preparations industry.
What exchange does APLS trade on?
Apellis Pharmaceuticals, Inc. (APLS) trades on the Nasdaq.
Where is Apellis Pharmaceuticals, Inc. incorporated?
Apellis Pharmaceuticals, Inc. is incorporated in DE.
When was Apellis Pharmaceuticals, Inc. (APLS)'s most recent SEC filing?
Apellis Pharmaceuticals, Inc. (APLS)'s most recent SEC filing is a Form 10-Q for the period ended 2026-03-31, filed with the SEC on 2026-05-07.
What is APLS's EPS (earnings per share)?
Apellis Pharmaceuticals, Inc. (APLS)'s trailing twelve month EPS is $1.04 as of 2026-03-31.
What is APLS's ROE (return on equity)?
Apellis Pharmaceuticals, Inc. (APLS)'s trailing twelve month Return on Equity (ROE) is 46.02% as of 2026-03-31.
What is APLS's ROA (return on assets)?
Apellis Pharmaceuticals, Inc. (APLS)'s trailing twelve month Return on Assets (ROA) is 14.10% as of 2026-03-31.
What is APLS's ROIC (return on invested capital)?
Apellis Pharmaceuticals, Inc. (APLS)'s trailing twelve month Return on Invested Capital (ROIC) is 871.91% as of 2026-03-31.